Cover Image
市場調查報告書

CRISPR的全球:各國 (美國、加拿大、印度、中國、日本、英國)、企業簡介、佔有率、趨勢、分析、機會、市場區隔及2015∼2021年的預測

Global CRISPR Market Insights, Opportunity Analysis, Market Shares and Forecast 2016 - 2022

出版商 Occams Business Research & Consulting Pvt. Ltd. 商品編碼 348577
出版日期 內容資訊 英文 140 Pages
商品交期: 請詢問到貨日
價格
Back to Top
CRISPR的全球:各國 (美國、加拿大、印度、中國、日本、英國)、企業簡介、佔有率、趨勢、分析、機會、市場區隔及2015∼2021年的預測 Global CRISPR Market Insights, Opportunity Analysis, Market Shares and Forecast 2016 - 2022
出版日期: 2016年04月29日 內容資訊: 英文 140 Pages
簡介

全球CRISPR市場預計2015∼2021年,以年複合成長率43%擴大。CRISPR為簡便且有效率、成本效益高的新技術,由於進行高度研究的生物科技企業和製藥產業的引進擴展,促進市場擴大。

本報告提供與全球CRISPR市場相關調查、市場趨勢以及到2021年的收益預測成長率、產業趨勢、競爭、各國趨勢,加上進入的主要企業的簡介等彙整。

第1章 簡介

第2章 市場概要

  • CRISPR:簡介
  • 價值鏈分析
  • 主要的購買標準
  • 研究開發
  • CRISPR對傳統的遺傳基因編輯工具
  • CRISPR:新的配合措施
  • 策略性建議和結論

第3章 部門分析

第4章 市場決策因素

  • 促進要素
    • 藥物研發市場增加
    • 合成遺傳基因的需求
    • 出生時的遺傳病的罹患率上升
    • 與年齡有關的遺傳疾病
    • 醫療用研究開發預算的增加
    • 創業投資
  • 阻礙要素
    • CRISPR遺傳基因編輯工具的誤用相關倫理的問題
    • 受限的認識
    • 新興市場上限制
  • 課題
    • CRISPR遺傳基因編輯打開遺傳基因外科市場
    • 亞洲的新興研究開發受託市場
  • 機會
    • 專利侵害
    • 替代的遺傳基因編輯工具的登場

第5章 市場區隔

  • 各用途
  • 各終端用戶
  • 競爭情報

第6章 各地區分析

  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第7章 企業簡介

  • Thermo Fisher Scientific
  • Editas Medicine
  • Caribou Biosciences
  • CRISPR therapeutics
  • Intellia
  • Cellectis
  • Horizon discovery PLC
  • Sigma Aldrich
  • Precision biosciences
  • GenScript
  • Sangamo Biosciences Inc.
  • Lonza group limited
  • Integrated DNA technologies
  • New England Biolabs
  • Oregene Technologies
  • Transposgen Biopharmaceuticals

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: HBI-2021015

Clustered regularly-interspaced short palindromic repeats also known as CRISPR is a gene editing tool. CRIPSR commercialization began in 2012 with emergence of number of startups and venture capitalists and showing their interest in infusing money into this technology. Academic and research firms are the main consumers of CRISPR gene editing tool followed by biotechnology companies. The number of patents for CRISPR is outclassing the patents of other gene editing tools such as ZFN and TALEN. The market is driven by high demand for plasmids, synthetic genes and high quality gene slicing techniques. Growing drug discovery, biotechnology and proteomics markets are also driving the market growth.

The market is This is driven by the fact that CRISPR is a new technology which is simple, more efficient and cost effective as compared to its peers. High adoption both in biotech and pharma industry along with high level of research is also responsible for high growth rate.

The market for CRISPR technology is niche. The number of companies are still very less and most of the companies are start-ups which are going through rounds of funding. Some of the major companies include Editas, Intellia, Sigma Eldrich, Oregene, Gene Script, Thermo Fisher Scientific and others. Most of the companies are working on developing CRISPR products along with the approval and commercialization of such products. These companies have successfully attracted major investments from big VC firms and companies such as Google and DuPont. These companies are relying on the disruptive nature of the technology. CRISPR has the capability to open new markets for gene surgery and genetically modified organisms. However, there are major concerns from the scientific community regarding the misuse of such technology in human cloning. Geographically North America leads the market race followed by Europe and Asia Pacific.

Companies profiled include

  • 1. Thermo Fisher Scientific
  • 2. Editas Medicine
  • 3. Caribou Biosciences
  • 4. CRISPR therapeutics
  • 5. Intellia
  • 6. Cellectis
  • 7. Horizon discovery PLC
  • 8. Sigma Aldrich
  • 9. Precision biosciences
  • 10. GenScript
  • 11. Sangamo Biosciences Inc.
  • 12. Lonza group limited
  • 13. Integrated DNA technologies
  • 14. New England Biolabs
  • 15. Oregene Technologies
  • 16. Transposgen Biopharmaceuticals

This Occams Research report covers

  • 1. Historical data
  • 2. Revenue forecasts, growth rates and CAGR up to 2021
  • 3. Industry Analysis
  • 4. Competitive Analysis
  • 5. Key geographic growth data

Table of Contents

1. Executive Summary

  • 1.1. Estimation Methodology

2. Market Overview

  • 2.1. CRISPR- Introduction
  • 2.2. Value chain analysis
  • 2.3. Key buying criteria
  • 2.4. Research and development
    • 2.4.1. Patent analysis
  • 2.5. CRISPR vs. Conventional gene editing tools
    • 2.5.1. TALEN
    • 2.5.2. ZFN
  • 2.6. CRISPR: Novel initiatives
    • 2.6.1. CRISPR/Cas9 technology
    • 2.6.2. CRISPR as a gene editing tool to treat genetic disorders.
    • 2.6.3. CRISP as a gene editing tool in drug development.
  • 2.7. Strategic Recommendation and conclusion

3. Sector Analysis

  • 3.1. Gene Editing Market

4. Market Determinants

  • 4.1. Drivers
    • 4.1.1. Rise in drug discovery market
    • 4.1.2. Demand for synthetic genes
    • 4.1.3. High prevalence of genetic birth disorders
    • 4.1.4. Age related genetic disorders
    • 4.1.5. Rise in the healthcare research and development budgets
    • 4.1.6. Venture capital
  • 4.2. Restraints
    • 4.2.1. Ethical issues related to misuse of CRISPR gene editing tool
    • 4.2.2 Limited awareness
    • 4.2.3. Limited presence in Emerging markets
  • 4.3. Opportunities
    • 4.3.1 CRISPR gene editing can open the market for gene surgery.
    • 4.3.2. Emerging contract research market in Asia
  • 4.4. Challenges
    • 4.4.1. Patent infringement
    • 4.4.2. Presence of alternative gene editing tools

5. Market Segmentation

  • 5.1. By Application
    • 5.1.1. Genome Editing
    • 5.1.2. Genetic engineering
    • 5.1.3. gRNA Database/Gene Library
    • 5.1.4. CRISPR Plasmid
    • 5.1.5. Human Stem Cells
    • 5.1.6. Genetically modified organisms/crops
    • 5.1.7. Cell line engineering
  • 5.2. By End user
    • 5.2.1. Biotechnology companies
    • 5.2.2. Pharmaceutical companies
    • 5.2.3. Academic Institutes
    • 5.2.4. Research and development institutes
  • 5.3. Competitive Intelligence
    • 5.3.1. Merger and Acquisitions
    • 5.3.2. Innovation
    • 5.3.3. Venture capital funding

6. Geographical Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. United Kingdom
    • 6.2.2. France
    • 6.2.3. Germany
    • 6.2.4. Spain
    • 6.2.5. Italy
  • 6.3. Asia Pacific
    • 6.3.1. China
    • 6.3.2. Japan
    • 6.3.3. India
  • 6.4. Rest of the world

7. Company Profiling

  • 1. Thermo Fisher Scientific
  • 2. Editas Medicine
  • 3. Caribou Biosciences
  • 4. CRISPR therapeutics
  • 5. Intellia
  • 6. Cellectis
  • 7. Horizon discovery PLC
  • 8. Sigma Aldrich
  • 9. Precision biosciences
  • 10. GenScript
  • 11. Sangamo Biosciences Inc.
  • 12. Lonza group limited
  • 13. Integrated DNA technologies
  • 14. New England Biolabs
  • 15. Oregene Technologies
  • 16. Transposgen Biopharmaceuticals
Back to Top